CD34 and myelodysplastic syndrome: Altogether, these results suggest that assessment of the PI of NRBC, and potentially also of other compartments of BM precursors (e.g.: myeloid CD34+ HPC), could significantly contribute to a better management of MDS patients, potentially also during monitoring of the effects of new drugs and therapeutical strategies.